Protein Degradation, Metabolic

TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases

2 months ago talkbio0Tagged cellular targeting, Clinical Nurse Specialists, degraders, Neurodegenerative Disorders, Plant seeds, Protein Degradation, Metabolic, TRIM21, TRIMTAC

targeted protein degradation, neurodegenerative diseases, TRIM21, TRIMTAC degraders, CNS therapeutics, seed funding, biotech startup

Neomorph Secures $1.6 Billion Deal with AbbVie to Develop Molecular Glue Degraders for Oncology and Immunology

3 months ago talkbio0Tagged AbbVie, Biotechnology, Drug Development, Immunology, molecular glue, Neomorph, Neoplasms, pharmaceutical partnership, Protein Degradation, Metabolic

Neomorph, AbbVie, molecular glue degraders, oncology, immunology, protein degradation, drug development, biotechnology, pharmaceutical partnership.

Neomorph Secures Third Major Collaboration with AbbVie for Molecular Glue Degraders Worth Up to $1.64 Billion

3 months ago talkbio0Tagged AbbVie, Biotechnology, Immunology, molecular glue, Neomorph, Neoplasms, pharmaceutical collaboration, Protein Degradation, Metabolic

Neomorph, AbbVie, molecular glue degraders, protein degradation, oncology, immunology, biotechnology, pharmaceutical collaboration

Kymera Therapeutics Shifts Focus to Immunology, Scaling Back Oncology Efforts

6 months ago talkbio0Tagged Immunology, IRAK4 gene, Kymera, Neoplasms, Protein Degradation, Metabolic, STAT6, TYK2 gene

Kymera Therapeutics, Immunology, Oncology, Targeted Protein Degradation, IRAK4, STAT6, TYK2

Novartis and Monte Rosa Collaborate on $2.2B Molecular Glue Degrader Alliance

6 months ago talkbio0Tagged Biopharma, Collaboration, molecular glue, Monte Rosa, Neoplasms, Neurological diseases, Novartis, Protein Degradation, Metabolic

Novartis, Monte Rosa, molecular glue degraders, biopharma collaboration, protein degradation, oncology, neurological diseases

Novartis Invests $150M in Monte Rosa’s Molecular Glue Technology for Autoimmune Diseases

6 months ago talkbio0Tagged Autoimmune Diseases, biotech, Collaboration, molecular glue, Monte Rosa, Novartis, Protein Degradation, Metabolic, VAV1-degrader

Novartis, Monte Rosa, Molecular Glue, Protein Degradation, Autoimmune Diseases, MRT-6160, VAV1-degrader, Biotech Collaboration

Booster Therapeutics Launches with $15 Million Funding to Pioneer Proteasome Activator Therapies for Neurodegenerative Diseases

7 months ago talkbio0Tagged DCLRE1B gene, Health Ventures, Holdings, multicatalytic endopeptidase complex, Nerve Degeneration, Neurodegenerative Disorders, Proteasome Activator Therapies, Protein Degradation, Metabolic

Proteasome activator therapies, Neurodegenerative diseases, Booster Therapeutics, Novo Holdings, Apollo Health Ventures, 20S proteasome, Protein degradation, Neurodegeneration

AstraZeneca Acquires Pinetree’s EGFR Degrader for $45 Million Upfront

9 months ago talkbio0Tagged AstraZeneca, Cancer Therapeutic Procedure, Epidermal Growth Factor Receptor, licensing agreement, milestone payments, molecular glues, Neoplasms, Pinetree, Protein Degradation, Metabolic, protein degrader, royalties

AstraZeneca, Pinetree Therapeutics, EGFR degrader, protein degrader, oncology, licensing agreement, milestone payments, royalties, targeted protein degradation, molecular glues, cancer treatment

Takeda Ventures into Molecular Glue Degraders with Degron Collaboration

11 months ago talkbio0Tagged Degron, Drug Discovery, molecular glue, pharmaceutical collaboration, Protein Degradation, Metabolic, Takeda

Takeda, Degron, molecular glue degraders, pharmaceutical collaboration, targeted protein degradation, drug discovery.